Clinical Trials
12 trialsNCT04669496 2025-09-04
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT07134218 2025-08-21
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
Changhai Hospital
Phase 2/3 Not yet recruiting
NCT01781338 2025-02-27
ADAPT
West German Study Group
Phase 2/3 Completed
NCT06769919 2025-01-10
A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
Xijing Hospital
Phase 2/3 Not yet recruiting
NCT04973306 2022-06-30
iCROSS
Shanghai Zhongshan Hospital
Phase 2/3 Recruiting
NCT03623737 2022-06-07
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
National Taiwan University Hospital
Phase 2/3 Unknown
NCT04968002 2021-07-20
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT00397761 2021-02-17
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
Medstar Health Research Institute
Phase 2/3 Withdrawn
NCT04025437 2019-09-04
Neoadjuvant Radiotherapy for HCC Involving Type I PVTT
Guangxi Medical University
Phase 2/3 Unknown
NCT02584556 2019-06-04
Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT01458717 2018-05-02
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
Seoul National University Hospital
Phase 2/3 Completed
NCT02882269 2016-08-30
Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2/3 Unknown